TL;DR
This study identifies potential blood-based biomarkers for predicting long-term outcomes in lacunar infarction (LACI) patients by analyzing medium-sized extracellular vesicles (MEVs) from convalescent plasma. The findings reveal a distinct MEV proteome compared to smaller EVs and suggest that altered proteins are primarily involved in cellular processes like oxygen-glucose deprivation and iron homeostasis, rather than traditional targets like inflammation.
What Problem Does This Paper Address?
Lacunar infarction (LACI), a common type of ischemic stroke, often leads to poor long-term prognoses due to recurrent vascular events or the development of dementia. Current clinical data makes it difficult to predict these adverse outcomes, leaving a critical gap in patient management and preventative strategies. The authors aim to address this by discovering novel blood-based biomarkers that can serve as a complementary tool to existing methods for predicting LACI prognosis. They hypothesize that extracellular vesicles (EVs) in the blood, particularly medium-sized ones (MEVs), may carry signatures of these underlying pathologies, and that analyzing them from convalescent plasma (after the acute inflammatory phase) can provide a more stable and specific picture for biomarker discovery.
Methods
The researchers employed a quantitative proteomics approach using isobaric tags for relative and absolute quantification (iTRAQ) coupled with 2D-LC-MS/MS. Plasma samples from LACI patients, categorized by their long-term outcomes (no adverse outcome, recurrent vascular event, or cognitive decline), and healthy controls were used. Medium-sized extracellular vesicles (MEVs) were isolated from pooled plasma samples using sequential centrifugation and ultracentrifugation. The proteomic data was then analyzed using various bioinformatics tools, including Gene Ontology (GO) enrichment analysis, to identify biological processes and cellular components associated with the altered proteins. Correlation analysis was used to compare the proteomic profiles between different patient groups and between MEVs and small extracellular vesicles (SEVs).
Datasets
The study utilized plasma samples collected from 45 LACI patients and 17 healthy controls. The LACI patients were prospectively followed for up to five years to categorize them into three groups:
- NAO (No Adverse Outcome): Patients who did not experience recurrent vascular events or cognitive decline.
- RVE (Recurrent Vascular Event): Patients who experienced a recurrent vascular event.
- CD (Cognitive Decline): Patients whose cognitive status declined.
The mass spectrometry raw data has been deposited in the ProteomeXchange Consortium via the PRIDE partner repository (identifier: PXD032225). Analyzed, classified, and curated data is also available at a provided web resource.
Key Insights and Ideas
- MEVs as a distinct biomarker source: The study highlights that MEVs have a significantly different proteome (~85%) compared to smaller extracellular vesicles (SEVs) from the same plasma, suggesting they capture unique biological information.
- Convalescent plasma is key: By analyzing plasma collected after the acute phase of stroke, the researchers aimed to bypass the transient inflammatory response, potentially revealing more stable and specific prognostic markers.
- Beyond inflammation: The identified altered proteins in LACI patients are largely not linked to commonly studied processes like coagulation or inflammation, but rather to oxygen-glucose deprivation, endo-lysosomal trafficking, glucose transport, and iron homeostasis. This suggests a shift in focus for LACI biomarker research.
- Adverse outcomes linked to proteomic changes: Patients with adverse outcomes (RVE and CD) showed a higher number of altered proteins compared to the NAO group, and these alterations were predominantly decreases in protein abundance.
- RVE and CD proteomes are similar: A strong positive correlation was observed between the proteomic profiles of RVE and CD groups, suggesting shared underlying pathological mechanisms or consequences.
Key Results
- 573 proteins quantified: The analysis identified 573 proteins in the MEV-enriched plasma samples with high confidence.
- 146 altered proteins: Out of these, 146 proteins showed significant changes in abundance in at least one LACI group compared to healthy controls.
- Predominantly decreased abundance: The majority of these altered MEV proteins were found to be reduced in abundance in LACI patients.
- Specific biological processes implicated: The deregulated MEV proteome was preferentially associated with cellular processes like oxygen-glucose deprivation, endo-lysosomal trafficking, glucose transport, and iron homeostasis.
- Inflammation-related proteins not enriched: Notably, inflammation-related proteins were not significantly enriched in the altered MEV proteome, supporting the strategy of using convalescent plasma.
Limitations and Future Work
The authors acknowledge several limitations:
- Sample storage duration: Plasma samples were stored for up to 12 years, which could impact protein stability and comparability with other studies.
- Lack of sex and smoking matching: The study groups were not matched for sex and smoking, which could be confounding factors.
- Limited sample amount: The small sample volume precluded the use of single vesicle-based imaging or particle analysis techniques for purity testing.
- No WB/ELISA validation: The limited availability of plasma and low MEV yield prevented validation of candidate biomarkers using Western Blot or ELISA.
- Causality unclear: As a single-timepoint snapshot, the study cannot establish causality between LACI and the identified biomarkers; it's unclear if the changes precede or follow the event.
- Nature of changes unknown: The study cannot determine if the observed changes are palliative, restorative, or simply bystanders.
Future work should focus on:
- Large-scale validation: Validating the shortlisted candidate biomarkers on independent cohorts.
- Multi-marker panels: Developing panels of biomarkers to improve prediction sensitivity and specificity.
- Longitudinal studies: Conducting time-series analyses to understand the temporal dynamics and causality of biomarker changes.
- Investigating sex-specific effects: Exploring potential sex-specific differences in biomarker profiles.
Summary updated